InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) released preliminary financial results for the third quarter of 2022, revealing record revenue estimated to be CA$39 million, 63% over the revenues of the third quarter of 2021 and sequential growth of over 6%.
Preliminary Q3 2022 Financial Highlights and Milestones
-
Eleventh consecutive quarter of growth representing an annualized run rate of over CA$155 million.
-
Revenue growth expected to continue in Q4 2022.
-
Solid demand for Canndoc’s branded products and expansion of the company’s medical cannabis dispensing operations.
-
Continued expansion of the company’s branded products portfolio, launching more than 10 new GMP SKUs during the quarter.
-
Continued expansion of the company’s medical cannabis dedicated pharmacy chain to a of total 25 locations as of the end of the third quarter.
-
Continued execution of the company’s global expansion plan.
The company plans to file its full financial results for the third quarter on November 15th , 2022.
Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.
Photo: Benzinga; Sources: courtesy of Kindel Media via Pexels
Related News
InterCure Q2 2022 Revenue Grows 119%, What About Profit?
Clever Leaves 2Q: Neutraceuticals Up, Preparing For Cannabis Flower Exports From Colombia
Israel’s Marijuana Bubble Bursts: Tel Aviv Stock Exchange Eliminates TA-Cannabis Index, Ending Three-Year High